For the Inventor, By the Inventor

Enter assignee name

Allschwil, Switzerland

Actelion Pharmaceuticals Ltd

USPTO Granted Patents = 217

CIPO Patents = 46

EPO Patents = 143

Trademarks = 30

Forward Citations = 1,056

Loading Chart...

Loading Chart...

195 inventors (with patents filed for the assignee):

Martin Bolli (50 out of 66 patents)

Christoph Boss (43 out of 59 patents)

Oliver Nayler (37 out of 38 patents)

4. Boris Mathys (32 out of 34 patents)

5. Claus Mueller (32 out of 36 patents)

6. Hamed Aissaoui (31 out of 38 patents)

7. Christian N Hubschwerlen (29 out of 61 patents)

8. Martine Clozel (27 out of 43 patents)

9. Thierry Sifferlen (27 out of 40 patents)

10. Thomas Weller (24 out of 54 patents)

11. Kurt Hilpert (22 out of 44 patents)

12. Georg Rueedi (21 out of 25 patents)

13. Jean-Philippe Surivet (21 out of 27 patents)

14. Sylvia Richard-Bildstein (20 out of 28 patents)

15. Markus Gude (20 out of 27 patents)

Core Competencies:

Pulmonary Arterial Hypertension

Selexipag

S1P Receptor Agonists

Macitentan

NADPH Oxidase 4 Inhibitors

Tricyclic Compounds

Azetidine Amide Derivatives

Antibacterial Agents

Pharmaceutical Compositions

Chronic Thromboembolic Pulmonary Hypertension

Therapeutic Compositions

Pyrimidine Intermediates

217 patents: Sort by Forward Citations

1. 12485119 - Methods of treating pulmonary arterial hypertension (2025-12-02),

2. 12419887 - Transitioning patients treated for pulmonary arterial hypertension to selexipag (2025-09-23),

3. 12121516 - Pharmaceutical composition comprising selexipag (2024-10-22),

4. 11771683 - Dosing regimen for a selective S1Preceptor agonist (2023-10-03),

5. 11723896 - Pharmaceutical combination comprising ponesimod (2023-08-15),

6. 11672783 - Pharmaceutical combination comprising a selective S1P1 receptor agonist (2023-06-13),

7. 11648249 - Stable pharmaceutical compositions comprising a pyrimidine-sulfamide (2023-05-16),

8. 11612600 - Pharmaceutical composition comprising macitentan for the treatment of chronic thromboembolic pulmonary hypertension (2023-03-28),

9. D974921 - Pharmaceutical package (2023-01-10),

10. 11464777 - Pharmaceutical composition for the treatment of pulmonary arterial hypertension (2022-10-11),

11. 11234980 - Pharmaceutical composition for the treatment of pulmonary arterial hypertension (2022-02-01),

12. 11136317 - NADPH oxidase 4 inhibitors (2021-10-05),

13. 11026927 - Pharmaceutical combination comprising a selective S1P1 receptor agonist (2021-06-08),

14. 10946015 - Stable pharmaceutical compositions comprising a pyrimidine-sulfamide (2021-03-16),

15. 10857134 - Dosing regimen for a selective S1Preceptor agonist (2020-12-08),

Actelion Pharmaceuticals Ltd is a Swiss biopharmaceutical company specializing in the discovery, development, and commercialization of innovative drugs for rare diseases. Established in 1997, Actelion focuses on areas such as pulmonary arterial hypertension, endothelial dysfunction, and lysosomal storage diseases. With a strong emphasis on research and development, Actelion has a diverse pipeline of potential therapies and is dedicated to improving the lives of patients with rare and severe conditions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

217 Patents

#1 in Allschwil

#75 in Switzerland

#3,817 in the World

Allschwil, Switzerland

Actelion Pharmaceuticals Ltd

Forward Citations = 1,056

195 inventors:

Martin Bolli (50 out of 66 patents)

Christoph Boss (43 out of 59 patents)

Oliver Nayler (37 out of 38 patents)

4. Boris Mathys (32 out of 34 patents)

5. Claus Mueller (32 out of 36 patents)

Please report any incorrect information to support@idiyas.com

Loading…